Estrogen Receptor alpha Monoclonal Antibody (1D5) (MA5-13191)
Electronics | December-1 2021 - Browse Articles
Tyrosinase Monoclonal Antibody (T311) (MA5-14177)
Neuronal mimicry generates an ecosystem critical for brain metastatic growth of SCLC | bioRxiv
Electronics | December-1 2021 - Browse Articles
Tyrosinase Monoclonal Antibody (T311) (MA5-14177)
Cancers | Free Full-Text | Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy | HTML
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemo... : Diseases of the Colon & Rectum
Content Editorial
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia | Science Translational Medicine
IJMS | Free Full-Text | HRness in Breast and Ovarian Cancers | HTML
Materials | February-2 2021 - Browse Articles
Neuronal mimicry generates an ecosystem critical for brain metastatic growth of SCLC | bioRxiv
Cancers | Free Full-Text | Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy | HTML
Artificial Intelligence in Cancer
Estrogen Receptor alpha Monoclonal Antibody (6F11) (MA5-13304)
Neuronal mimicry generates an ecosystem critical for brain metastatic growth of SCLC | bioRxiv
2008 - NKI / AvL
Platelet Factor 4 as a Novel Exosome Marker in MALDI-MS Analysis of Exosomes from Human Serum | Analytical Chemistry
Axon-like protrusions promote small cell lung cancer migration and metastasis | bioRxiv
Estrogen Receptor alpha Monoclonal Antibody (6F11) (MA5-13304)
Transcriptomic analyses of MYCN-regulated genes in anaplastic Wilms' tumour cell lines reveals oncogenic pathways and potential therapeutic vulnerabilities | bioRxiv
![PDF] The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment](https://i1.rgstatic.net/publication/26686178_The_impact_of_inter-observer_variation_in_pathological_assessment_of_node-negative_breast_cancer_on_clinical_risk_assessment_and_patient_selection_for_adjuvant_systemic_treatment/links/56a8c3e608ae860e02577b7a/largepreview.png "PDF] The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment")
PDF] The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment
IJMS | Free Full-Text | HRness in Breast and Ovarian Cancers | HTML
